Thank you for the question.
The pandemic brought to bear, as it was originally indicated, the importance of being able to produce vaccines in Canada for our own certainty but also to be able to support others as you have highlighted. We are going as fast as we possibly can without actually jeopardizing or putting at risk the importance of producing vaccines in a safe manner in accordance with good manufacturing practices.
The way the biologics manufacturing centre is intended to work is that we don't own the vaccine. We work with people who are vaccine sponsors, and we take that vaccine, such as the case with Novavax, and produce it either for the need in Canada, if we need it obviously, or for other countries in need, which would have to be where the Canadian approval and the vaccine sponsor have the authority to bring it to them.
Therefore, for us right now, we are, as I indicated, in the commissioning, qualification and validation, we have completed the pilot runs with the Novavax vaccine—